Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).

Trial Details

NCT ID
NCT05536505
Phase
PHASE2
Sponsor
Guangdong Association of Clinical Trials
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adjuvant treatment for MRD positivity
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Chongqing, China|29.56026,106.55771
  • Foshan, China|23.02677,113.13148
  • Fuzhou, China|26.06139,119.30611
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Written informed consent provided.
  • Males or females aged ≥18 years, \< 80 years.
  • Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
  • Target population is completely resected pathological stage IB-IIIB NSCLC with EGFR exon 19 deletions, L861Q mutation, G719X mutation and exon 21 L…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →